 CAMBRIDGE, Mass., May 23, 2021 PRNewswire -- Synlogic, Inc. Nasdaq: SYBX, a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on an investigational program to develop Synthetic BioticTM medicines for the treatment of inflammatory bowel disease IBD during Digestive Disease Week DDW, being held virtually May 21-23, 2021. 